Acumen Pharmaceuticals, Inc.

Northwestern University

Other

Abbott Laboratories Corporation

University of Southern California

Conjuchem Biotechnologies Inc.

Grant A Krafft

William L Klein

Mary P Lambert

Dominique P Bridon

Todd R Pray

William F Goure

Todd Morgan

Brett A Chromy

Caleb E Finch

Pat Wals

Irina Rozovsky

Ann Barlow

John C Russell

John W Erickson

Martin Robitaille

Catherine A Brennan

Lei Chang

Elaine Marie Brate

Wei-Qin Zhao

Kirsten L Viola

Dong Xie

Steven C March

Wlodzimierz Mandecki

Keeve D Jaffe

Vincent T Yue

Elena Afonina

Jun Liang

Sandra DeMeyer

Pauline T Velasco

Sara J Fernandez

Pascale N Lacor

Daliya Khuon

Jasna Jerecic

Yuesong Gong

Todd Pray

This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.

ADDL receptor polypeptides, polynucleotides and host cells for recombinant production

Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid &#x3b2;oligomers from amyloid &#x3b2;monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid &#x3b2;oligomers.

Methods of modifying amyloid &#x3b2; oligomers using non-peptidic compounds

Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A&#x3b2;monomers.

Methods of restoring cognitive ability using non-peptidic compounds

Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid &#x3b2; (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.

Monoclonal antibodies that target pathological assemblies of amyloid &#x3b2; (Abeta)

The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric A&#x3b2; peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric A&#x3b2; peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric A&#x3b2; peptide assemblies, also known as ADDLs, and ADDL-related assemblies.

Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

Long lasting fusion peptide inhibitors for HIV infection

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid &#x3b2; peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

Amyloid &#x3b2;  protein (globular assembly and uses thereof)

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid &bgr; peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

Amyloid &bgr; protein (globular assembly and uses thereof)

This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

Genetically engineered enzymes and their conjugates for diagnostic assays

Growing community of inventors

Glenview, IL, United States of America

Grant A Krafft